Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2023-03-24 | Ms. Xing has served as Executive Chair of the Board of Directors of Mundipharma China since 2022. ... Ms. Xing was appointed to the Board in March 2023 and is standing for election for the first time. ... No committees listed. No compensation stated. |
| 2024-03-22 | Ms. Xing has served as Executive Chair of the Board of Directors of Mundipharma China since 2022. Mundipharma is a multinational pharmaceutical leader. From 2019 to 2022, Ms. Xing held the position of Global Senior Vice President, President of Greater China for Envista Holdings Corporation (a dental equipment and supplies company). Prior to that, Ms. Xing served in numerous leadership roles at Eli Lilly and Company (a global pharmaceutical company), including Senior Director, Global New Product Planning and Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2018 to 2019, Senior Director, Global Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2015 to 2018, Vice President of Lilly China Oncology from 2012 to 2014 and Vice President of Corporate and Government Affairs and Market Access from 2010 to 2012, while based in Shanghai. Prior to Eli Lilly, from 2007 to 2010 Ms. Xing was Vice President and General Manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific. Ms. Xing also serves as Board advisor on the Board of Directors of Mars, Incorporated (a global manufacturer of confectionery, pet food and provider of animal care services). Committees: Management Development and Compensation. 2023 Director Compensation: $321,257. |
| 2025-03-28 | JULIE XING Age: 56 Independent Director since: 2023 Committees: Management Development and Compensation ... J. Xing 107,000 160,072 0 267,072 |
Data sourced from SEC filings. Last updated: 2026-02-03